Search PubMed⌕ Search

PubMed · 11710218

Metallabenzenes.

Abstract

Many similarities exist between metallabenzenes and conventional arenes. Among these similarities are structural features such as ring planarity and the absence of bond length alternation, spectroscopic features such as downfield chemical shifts for ring protons, and chemical reactions such as electrophilic aromatic substitution and arene displacement from (arene)Mo(CO)3. All of these features, taken together, strongly support the thesis that metallabenzenes represent a new class of aromatic compounds, one in which metal d orbitals participate fully with carbon p orbitals in the formation of ring pi-bonds. However, it is also apparent that metallabenzenes are much more prone to isomerization reactions than are conventional arenes. This appears to be particularly true of first-row and second-row metallabenzenes, where the metal-carbon bond strengths are weaker. In these systems, carbene migratory insertion often leads to cyclopentadienyl-metal products. pi-Coordination of metallabenzenes to other metal centers generally stabilizes the metallabenzene moieties while maintaining their aromatic character. Among metallabenzenes coordinated in this way, there are representatives from all three transition-metal rows (Fe, Ni, Mo, Ru, and Ir). The metal atom in pi-coordinated metallabenzenes is displaced out of the ring and away from the complexing metal center. The reason for this displacement in most cases appears to be steric repulsion between ligands on the two metal centers. However, other subtle effects may contribute. For example, metal displacement leads to more favorable internal angles at the alpha-carbons and a better orientation of C alpha p orbitals toward the complexing metal center. While no dominant synthetic strategy for constructing metallabenzenes has emerged, cyclization reactions involving metal-thiocarbonyl, metal-alkylidyne, and metal-alkylidene precursors have proved useful. In addition, approaches involving pentadienyl reagents as the source of ring carbons have yielded notable successes. Vinylcyclopropene reagents have recently led to isolation of the first example of a metallabenzene valence isomer--a metallabenzvalene--and its subsequent conversion to a planar metallabenzene. Finally, interligand attacks of butadienyls on carbonyls have produced a variety of transient oxy- or alkoxy-substituted metallabenzene species. The development of new synthetic approaches, particularly systematic approaches that can be used with a variety of transition metals, is the key issue facing metallabenzene chemists. One hundred and thirty-five years after Kekulé's celebrated dream, aromatic chemistry continues to be a fascinating and provocative research topic. Metallabenzenes represent one of the "new frontiers" that promise to keep aromatic chemistry vibrant well into the 21st century.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J R Bleeke. 2001. Metallabenzenes.. https://doi.org/10.1021/cr990337n

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗